Related Experiment Video
Updated: Apr 25, 2026

An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
Integration of Time-Varying Pharmacometric Modeling With Cox Regression for Time-to-Event Analysis in NONMEM
Chih-Wei Lin1, Po-Wei Chen1, Sameer Doshi1
1Clinical Pharmacology, Modeling and Simulation, Amgen Inc, Thousand Oaks, California, USA.
Abstract:
Although time-varying Cox regression modeling approaches have been developed, exposure-response analyses for time-to-event (TTE) endpoints often rely on static exposure covariates and may overlook the real-world dosing variability and drug concentration fluctuations over time. To better characterize pharmacokinetic (PK) or pharmacodynamic (PD) effects on TTE endpoints, a methodology was proposed to integrate time-varying pharmacometric models with Cox regression in the non-linear mixed effects modeling software, NONMEM. Clinical trial simulations were conducted with different sample sizes and dose levels, employing a one-compartment PK model, a bathtub-shaped function for event hazard, and an Imax model for concentration-hazard relationships. Model parameters were estimated based on partial likelihood using the first order approximation method in NONMEM, and results were compared to those obtained from parametric methods under different baseline hazard assumptions. The performance of the models using static and time-varying exposure metrics was also assessed. In the absence of a pre-specified baseline hazard, the proposed semi-parametric approach delivered robust parameter estimates and aligned with the parametric method with the correct baseline hazard assumption. The semi-parametric method outperforms other parametric approaches with incorrect baseline hazard assumptions. Furthermore, the semi-parametric method using time-varying exposure metrics outperforms those using static exposure metrics. The proposed methodology successfully integrates time-varying PK effects on TTE endpoints in the simulation study. It offers a flexible framework in NONMEM and can be extended to include other pharmacometric models with ordinary differential equations, thus enhancing model-informed decision-making for assessing TTE endpoints in drug development.
Related Concept Videos
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
Analysis of Population Pharmacokinetic Data
Model Approaches for Pharmacokinetic Data: Compartment Models
Two primary types of compartment models are recognized: mammillary and catenary. The more...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...

